• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

个性化益生元和益生菌补充剂对肠易激综合征症状的影响:一项开放标签、单臂、多中心临床试验。

Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial.

机构信息

Institute of Health Science, Health Science Business Division, Kirin Holdings Company, Limited, Fujisawa, Kanagawa 251-8555, Japan.

Soiken Inc., Chiyoda, Tokyo 101-0052, Japan.

出版信息

Nutrients. 2024 Oct 1;16(19):3333. doi: 10.3390/nu16193333.

DOI:10.3390/nu16193333
PMID:39408300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11478705/
Abstract

BACKGROUND/OBJECTIVES: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients.

METHODS

Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4.

RESULTS

The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention.

CONCLUSIONS

In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.

摘要

背景/目的:益生菌和益生元已被报道可改善肠易激综合征(IBS)的症状。然而,益生菌和益生元的效果可能因 IBS 亚型而异。本研究旨在调查基于肠道微生物群和 IBS 亚型的个性化益生元和益生菌补充剂对患者的影响。

方法

招募了腹泻型 IBS(IBS-D)、便秘型 IBS(IBS-C)和混合型 IBS(IBS-M)患者(每组 40 例;总计 120 例)。根据 IBS 亚型和肠道微生物群确定个性化的益生元和益生菌补充剂。患者接受补充剂治疗 4 周。主要结局是从基线到第 4 周 IBS 严重程度评分系统的变化。

结果

所有患者的 IBS 严重程度评分系统均显著降低(-38.0 [95%置信区间(CI):-53.6,-22.4];<0.001),IBS-D 患者(-44.5 [95% CI:-70.6,-18.5];=0.004)和 IBS-C 患者(-51.2 [95% CI:-79.4,-22.9];=0.002),但 IBS-M 患者则没有(-20.0 [95% CI:-48.0,8.1];=0.47)。在这项研究中,没有观察到与干预有因果关系的严重不良事件。

结论

总之,根据个体肠道微生物群和 IBS 亚型选择的个性化益生元和益生菌补充剂可能缓解 IBS 症状的严重程度,特别是在 IBS-C 和 IBS-D 患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/4db3010da6d7/nutrients-16-03333-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/92f3c14ea57a/nutrients-16-03333-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/4879b9012a23/nutrients-16-03333-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/4db3010da6d7/nutrients-16-03333-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/92f3c14ea57a/nutrients-16-03333-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/4879b9012a23/nutrients-16-03333-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f7/11478705/4db3010da6d7/nutrients-16-03333-g003.jpg

相似文献

1
Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial.个性化益生元和益生菌补充剂对肠易激综合征症状的影响:一项开放标签、单臂、多中心临床试验。
Nutrients. 2024 Oct 1;16(19):3333. doi: 10.3390/nu16193333.
2
Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.金合欢纤维或益生菌补充剂缓解便秘为主的 IBS 患者的胃肠道不适:为期 4 周的随机双盲安慰剂对照干预试验。
Eur J Nutr. 2024 Aug;63(5):1983-1994. doi: 10.1007/s00394-024-03398-8. Epub 2024 Apr 23.
3
Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.肠道微生物群的调节:聚焦于肠易激综合征的治疗
Postgrad Med. 2017 Nov;129(8):872-888. doi: 10.1080/00325481.2017.1383819. Epub 2017 Oct 13.
4
Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet.肠易激综合征的胃肠道微生物群改变及其饮食调节:益生菌、益生元和低 FODMAP 饮食。
Proc Nutr Soc. 2016 Aug;75(3):306-18. doi: 10.1017/S0029665116000021. Epub 2016 Feb 24.
5
The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.益生菌、益生元、合生菌和粪便微生物群移植治疗肠易激综合征的疗效:系统评价和网络荟萃分析。
Nutrients. 2024 Jul 2;16(13):2114. doi: 10.3390/nu16132114.
6
A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.一项关于多菌株益生菌制剂(Bio-Kult®)用于治疗腹泻型肠易激综合征的随机安慰剂对照临床试验。
BMC Gastroenterol. 2018 May 25;18(1):71. doi: 10.1186/s12876-018-0788-9.
7
The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.多菌种益生菌混合物对腹泻型肠易激综合征症状和粪便微生物群的影响:一项随机、双盲、安慰剂对照试验。
J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1.
8
Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.益生元、益生菌和合生元对肠易激综合征及慢性特发性便秘的疗效:系统评价与荟萃分析
Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562. doi: 10.1038/ajg.2014.202. Epub 2014 Jul 29.
9
Efficacy of HA-196 and R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.HA-196 和 R0175 缓解肠易激综合征(IBS)症状的疗效:一项随机、安慰剂对照研究。
Nutrients. 2020 Apr 21;12(4):1159. doi: 10.3390/nu12041159.
10
Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis.益生菌、益生元及合生元治疗肠易激综合征的疗效与安全性:一项系统评价与荟萃分析
Sultan Qaboos Univ Med J. 2020 Feb;20(1):e13-e24. doi: 10.18295/squmj.2020.20.01.003. Epub 2020 Mar 9.

引用本文的文献

1
Effects of short-chain fatty acid-producing probiotic metabolites on symptom relief and intestinal barrier function in patients with irritable bowel syndrome: a double-blind, randomized controlled trial.短链脂肪酸产生型益生菌代谢产物对肠易激综合征患者症状缓解及肠道屏障功能的影响:一项双盲、随机对照试验
Front Cell Infect Microbiol. 2025 Jun 12;15:1616066. doi: 10.3389/fcimb.2025.1616066. eCollection 2025.
2
Beyond hormones: 3PM approach to vaginal microbiota dynamics in postmenopausal women.超越激素:绝经后女性阴道微生物群动态变化的下午3点研究方法
EPMA J. 2025 Apr 15;16(2):299-350. doi: 10.1007/s13167-025-00406-7. eCollection 2025 Jun.
3

本文引用的文献

1
The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.益生菌、益生元、合生菌和粪便微生物群移植治疗肠易激综合征的疗效:系统评价和网络荟萃分析。
Nutrients. 2024 Jul 2;16(13):2114. doi: 10.3390/nu16132114.
2
A double-blind, randomized, placebo-controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females.一项双盲、随机、安慰剂对照研究,评估益生菌补充剂对女性肠易激综合征症状的影响。
Neurogastroenterol Motil. 2024 Apr;36(4):e14751. doi: 10.1111/nmo.14751. Epub 2024 Jan 29.
3
Effect of DSW3805 Isolated from Kimchi for Gut Health Attenuating Colonic Inflammation in a Dextran Sulfate Sodium-Induced Mouse Model.
从泡菜中分离出的DSW3805对肠道健康的影响:在葡聚糖硫酸钠诱导的小鼠模型中减轻结肠炎症
Nutrients. 2025 Apr 3;17(7):1259. doi: 10.3390/nu17071259.
4
Periodic Changes in the Gut Microbiome in Women with the Mixed Type of Irritable Bowel Syndrome.混合型肠易激综合征女性肠道微生物群的周期性变化
Biomedicines. 2025 Mar 7;13(3):652. doi: 10.3390/biomedicines13030652.
5
Very-Low-Absorbable Geraniol for the Treatment of Irritable Bowel Syndrome: A "Real-World" Open-Label Study on 1585 Patients.用于治疗肠易激综合征的极低吸收性香叶醇:一项针对1585例患者的“真实世界”开放标签研究。
Nutrients. 2025 Jan 17;17(2):328. doi: 10.3390/nu17020328.
6
Probiotic Microorganisms in Inflammatory Bowel Diseases: Live Biotherapeutics as Food.炎症性肠病中的益生菌微生物:作为食品的活体生物治疗剂
Foods. 2024 Dec 18;13(24):4097. doi: 10.3390/foods13244097.
Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.
肠易激综合征中的肠道菌群失调:关于与疾病亚型的相关性及新治疗意义的叙述性综述
Microorganisms. 2023 Sep 22;11(10):2369. doi: 10.3390/microorganisms11102369.
4
Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.益生菌治疗肠易激综合征的疗效:系统评价与荟萃分析
Gastroenterology. 2023 Nov;165(5):1206-1218. doi: 10.1053/j.gastro.2023.07.018. Epub 2023 Aug 3.
5
Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.便秘型肠易激综合征(IBS-C):不同营养模式对肠道菌群失调和症状的影响。
Nutrients. 2023 Mar 28;15(7):1647. doi: 10.3390/nu15071647.
6
Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review.肠易激综合征与肠道微生物群:综述
J Clin Med. 2023 Mar 28;12(7):2558. doi: 10.3390/jcm12072558.
7
Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study.日本、中国和韩国肠易激综合征的患病率:一项国际横断面研究。
J Neurogastroenterol Motil. 2023 Apr 30;29(2):229-237. doi: 10.5056/jnm22037.
8
Gut microbiome signatures reflect different subtypes of irritable bowel syndrome.肠道微生物群特征反映了不同亚型的肠易激综合征。
Gut Microbes. 2023 Jan-Dec;15(1):2157697. doi: 10.1080/19490976.2022.2157697.
9
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.罗马IV型肠易激综合征中与较低疾病特异性和一般健康相关生活质量相关的因素。
Aliment Pharmacol Ther. 2023 Feb;57(3):323-334. doi: 10.1111/apt.17356. Epub 2022 Dec 21.
10
Artificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome.基于人工智能的个性化饮食:用于肠易激综合征的初步临床研究。
Gut Microbes. 2022 Jan-Dec;14(1):2138672. doi: 10.1080/19490976.2022.2138672.